Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Summary
The purpose of this pilot study is to evaluate the safety of nanoliposomal irinotecan in combination with 5-FU and leucovorin with paricalcitrol as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma who have progressed on a gemcitabine-based regimen.
General Information
NCT#: NCT03883919
Study ID: 201905201
Trial Phase: Pilot
Trial Sponsor: Washington University, Ipsen Biopharmaceuticals
Therapies Used in This Trial: Fluorouracil, Leucovorin, irinotecan liposome injection, Paricalcitol